ABPI announces new code of practice

The Association of the British Pharmaceutical Industry (ABPI) said that it has renewed its code of practice for contact between pharmaceutical companies, professionals and others.

The body said that from January 1st firms will be required to give information of possible adverse drug side effects within all promotional literature relating to their products. The relationship between professionals and companies will also be further restricted, placing regulations on perks such as travel and hospitality.

Companies which do not adhere to the code of practice, or have complaints filed against them which are considered “serious,” will have the details publicised in the medical press.

“This has been a fundamental review of the code and follows a far-reaching public consultation exercise. We have listened to all these comments and taken action accordingly,” said Vincent Lawton, president of the industry group.

“As well as the changes to the code itself, we want to ensure that more people and organisations know about it, its provisions and understand how it works.” He said that the ABPI has taken on a press officer to publicise the code throughout the year.

The code also includes a complete ban on pharmaceutical competitions, a reduction in the allowed number of pages of advertising, and greater disclosure into how drugs companies work with patient or public interest groups.

© Adfero Ltd